NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a
recent study announced positive early results from a PSMA 617-Lu177
study conducted by a leading global pharmaceutical company.
The report provides strong indications for analogous success in
similar technology the Company is helping to develop.
The article can be accessed at:
Anthony Hayes, CEO of AIkido
Pharma, stated, "As a rising tide lifts all boats, these results
indicate the strength of our prior investment in this technology
field. These early reports indicate there is strong evidence
that developing radioligand therapies have the potential to be an
alternative cancer treatment and provide positive outcomes for
patients with advanced prostate cancer. The Company's stock
price has been down recently, but we believe these positive results
from the Novartis Phase III study provides an incremental proof
point that reinforces our confidence in the radiopharmaceutical
space, PSMA and our investment in this technology. With
testing data for our technology expected in Q2 of this year, we are
excited about the results and the advancement of this
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Brett Maas, Managing
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.